Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
16 results
  • Melanoma, Pancreatic Cancer, Lung Cancer, Colorectal Cancer

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations (View details on

  • Pancreatic Cancer, Gastric (Stomach) Cancer, Bladder Cancer, Liver Cancer, Sarcoma, Endometrial Cancer, Esophageal Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on

  • Colorectal Cancer, Pancreatic Cancer, Lung Cancer

20-671          Phase II

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation (View details on

  • Ovarian Cancer, Pancreatic Cancer, Lung Cancer, Melanoma, Esophageal Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Chordoma, Endometrial Cancer

20-650          Phase II

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology (View details on

  • Pancreatic Cancer

20-607          Phase II

A phase II, open label, randomized, parallel arm study of NIS793 (with or without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) (View details on

  • Pancreatic Cancer, Head and Neck Cancer, Lymphoma, Kidney Cancer, Colorectal Cancer, Melanoma, Neuroendocrine

21-447          Phase I

An Open-Label Study of ALPN-202 Combined with PD-1 Inhibition in Subjects with Advanced Malignancies (NEON-2) (View details on

  • Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Gallbladder and Bile Duct Cancers, Ovarian Cancer

21-121          Phase II

First in Human Phase 1/2 Trial of ELI-002 Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors (View details on

Showing 1 - 10 of 16 results